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Dear Editor,
Acute promyelocytic leukemia (APL) caused by the malig-
nant proliferation of bone marrow-derived cells, which is
driven by the chromosomal translocation, leading to the
fusion of the promyelocytic leukemia gene (PML) and the
retinoic acid receptor-a gene (RARA) (de The et al., 1990;
Goto et al., 2011). The oncogenic protein PML-RARA has
been found speciﬁcally in more than 95% APL patients and
is crucial for both the pathogenesis and therapeutics of APL
(de The et al., 1990; Zhou et al., 2007; Wang and Chen,
2008). Arsenic trioxide (AS2O3), an ancient traditional Chi-
nese medicine, has recently been adopted as the ﬁrst-line
treatment for APL patients by the National Comprehensive
Cancer Network (Wang and Chen, 2008; Zhu and Huang,
2014), which greatly improved the 5-year overall survival of
APL patients (Li et al., 2002; Zhou et al., 2007; Wang and
Chen, 2008; Lo-Coco et al., 2013). Mounting biological
studies revealed that AS2O3 cures APL by initiating PML-
RARA degradation through speciﬁc binding to the PML
moiety (Lallemand-Breitenbach et al., 2001; Zhang et al.,
2010). Mechanistically, AS2O3 binds directly to the dicys-
teine residues C212/213 located in the B2 domain of PML,
which induces PML oligomerization, NB formation,
SUMOylation, and ultimate degradation of PML (Lallemand-
Breitenbach et al., 2008; Jeanne et al., 2010; Zhang et al.,
2010).
Unfortunately, although the application of AS2O3 dra-
matically promoted the clinical remission of APL patients,
some patients still experienced a relapse with AS2O3
treatment in the clinical practice (Goto et al., 2011; Zhu
et al., 2014). Therefore, characterizing the molecular
mechanism of AS2O3 resistance is critical for optimizing
the clinical application of AS2O3. Recently, it has been
reported that 9 arsenic-resistant APL patients harboring
PML-RARA mutations, including S214L, A216T, L217F
and S220G which locate in the B2 domain of PML-RARA
(Zhu et al., 2014). Among them, 8 patients could not be
induced a second remission and died (Zhu et al., 2014).
These clinical observations provided in vivo evidence that
mutations in the hot-spot domain (C212-S220) of PML-
RARA might contribute to the unresponsiveness to AS2O3
treatment, and the underlying molecular mechanism of
PML-RARA mutations with AS2O3 resistance deserve
further study.
In this study, we constructed the expression plasmids of
PML-RARA-S214L, A216T, L217F and S220G that were
clinically observed in arsenic-resistant APL patients
(Fig. 1A). APL cell line NB4 cells were transfected with the
indicated plasmid and a time-course study was performed
with 2 µmol/L AS2O3. As shown in Fig. 1B, AS2O3 induced a
signiﬁcant degradation of wild-type PML-RARA. Similar
results were observed with the mutants L217F and S220G.
Conversely, addition of AS2O3 did not induce the degrada-
tion of S214L, even the treatment time was extended to 36 h.
While in the case of A216T, the abundance of protein
decreased moderately compared with wild-type PML-RARA.
Quantiﬁcation for the protein abundance of distinct PML-
RARA mutants with AS2O3 treatment revealed that muta-
tions occurred in different sites of PML-RARA B2 domain
response distinctly to AS2O3 treatment (Fig. 1C). The unre-
sponsiveness of mutant S214L to AS2O3 indicates the
essential role of Ser214 amino residue in mediating AS2O3-
induced physiological consequence.
AS2O3-induced degradation of PML-RARA is initiated by
the direct binding between AS2O3 and PML-RARA (Jeanne
et al., 2010). As different degradation pattern was observed
above in the PML-RARA mutants, to detect the binding
afﬁnity of AS2O3 to different PML-RARA mutants, strepta-
vidin agarose afﬁnity assay was performed with
p-aminophenylarsine oxide (PAPAO) as the probe (Zhang
et al., 2010). PAPAO was conjugated to biotin, which was
designed as Biotin-As. The result showed that biotin-As
bound to PML-RARA, similar binding afﬁnity was observed
with PML-RARA-L217F and S220G (Fig. 1D and 1E). And
the mutant A216T showed a relatively decreased binding
afﬁnity compared with the wild-type PML-RARA. Conversely,
S214L mutation exhibited sharply diminished biotin-As
binding (Fig. 1D and 1E), similar to the mutant C212A which
has been demonstrated to mediate the direct arsenic binding
(Jeanne et al., 2010). These results indicate that Ser214,
together with the adjacent dicysteine motif C212/213, are
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Figure 1. The effects of AS2O3 on the degradation of PML-RARA mutants. (A) Schematic model of PML, RARA, and the fusion
protein. The functional domains of PML and RARA are indicated with black and gray, respectively. RING refers to the RING ﬁnger; B1
and B2, B-box motifs; C-C, coiled-coil; and DBD, DNA-binding domain. Black arrows indicate the break points of the fusion proteins
PML-RARA. The CC motif (C212/213) required for AS2O3 binding is underlined. The mutation sites Ser214, Ala216, Leu217 and
Ser220 were highlighted in bold. (B) NB4 cells transfected with different plasmids were treated with 2 µmol/L AS2O3 for the indicated
time and AS2O3-induced PML-RARA degradation was evaluated by Western blot using anti-Flag antibody. (C) Quantiﬁcation of the
relative protein level of PML-RARA mutants with AS2O3 treatment showed in Fig. 1B was calculated. The protein abundance of PML-
RARA without AS2O3 treatment (0 h) was presented as ‘1’ and the level of PML-RARA with AS2O3 treatment for the indicated time
was expressed relatively to this. The error bars represent standard error. (D) CHO cells transfected with indicated PML-RARA
mutants were treated with 10 µmol/L AS2O3 for 2 h. Cells were harvested and lysed in 8 mol/L urea buffer. The supernatant was
incubated with streptavidin agarose beads overnight at 4°C. After extensive wash, the streptavidin beads were resuspended in 30 µL
SDS-PAGE loading buffer. The binding of arsenic with PML-RARA was analyzed by Western blot. (E) The binding afﬁnity of PML-
RARA mutants with arsenic observed in Fig. 1D was quantiﬁed. The ratio was described relatively to the binding afﬁnity of wild-type
PML-RARA with arsenic.
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equally essential in mediating the arsenic-PML binding,
consistent with the data that S214L mutant is resistant to
AS2O3-induced degradation.
Upon the binding of arsenic to PML-RARA, PML-RARA
is subjected to hierarchical posttranslational modiﬁca-
tions, such as SUMOylation, which is required for the
responsiveness of PML-RARA to AS2O3 (Lallemand-
Breitenbach et al., 2008; Jeanne et al., 2010; Zhang et al.,
2010; Goto et al., 2011). Because distinct mutants of
PML-RARA exhibited different AS2O3 binding afﬁnity and
degradation pattern followed by AS2O3 treatment, we next
detected whether these mutants affect the basal
SUMOylation of PML-RARA. As expected, SUMOylated
PML bands were observed in cells transfected with wild-
type PML-RARA. In contrast, the SUMOylation level of
A216T elicited a decreased pattern, while mutation L217F
and S220G showed no signiﬁcant effect on PML-RARA
SUMOylation. Notably, no SUMOylation band was
observed for S214L (Fig. 2A). To conﬁrm the data of
S214L, the SUMOylated PML-RARA bands were detec-
ted with AS2O3 treatment. Compared with PML-RARA,
SUMOylated S214L was not detected with or without
AS2O3 treatment (Fig. 2B). The varying SUMOylation
pattern of PML-RARA mutants is correlated with the
degradation pattern of these mutants.
It has recently been demonstrated that AS2O3 exposure
triggers the nucleoplasmic PML transfers toward the nuclear
matrix and nuclear body (NB) (Jeanne et al., 2010; Goto
et al., 2011). To detect the transfer of different PML-RARA
mutants in response to AS2O3, we performed subcellular
fraction assay using 293T cells that expressing wild-type
PML-RARA or the mutants. As expected, in the presence of
AS2O3, PML-RARA was observed mostly in the insoluble
nuclear body fraction (Fig. 2C, lane 2). Similar results were
detected with the mutants of L217F and S220G (Fig. 2C,
lanes 8 and 10). Conversely, the transfer of S214L exhibited
no response to AS2O3 treatment (Fig. 2C, lanes 3 and 4).
The relative protein intensity in the soluble or insoluble
fraction was quantiﬁed and depicted in Fig. 2D. It has been
reported that PML-RARA forms multimerization via disulﬁde-
mediated covalent binding in response to AS2O3, and sub-
sequently triggers the NB formation (Jeanne et al., 2010).
Given that the essential role of Ser214 in AS2O3 response,
we performed immunoﬂuorescence assay to detect the
effect of mutation S214L on the subcellular localization of
PML-RARA. HeLa cells were transfected with the indicated
PML-RARA expression plasmids and treated with or without
AS2O3. Wild-type PML-RARA and mutant S220G were
detected in the nucleus as a microgranular pattern (Fig. 2E)
and the localization was sharply altered to a macrogranular
pattern in response to AS2O3 (Fig. 2E). Interestingly, S214L
was localized diffusely in the nucleus in the presence or
absence of AS2O3 (Fig. 2E), suggesting a non-responsive-
ness of S214L to AS2O3 treatment. Previous studies
demonstrate that the combination of all-trans retinoic acid
(ATRA) works better than AS2O3 alone in APL treatment.
Therefore, we hypothesized that combining ATRA with
AS2O3 might induce the degradation of S214L and A216T
mutants. As expected, AS2O3-ATRA triggered the degrada-
tion of S214L and A216T (Fig. 2F). These results suggest
that combination of AS2O3 with ATRA overcome the arsenic-
resistance of PML-RARA mutations.
In this study, we revealed the molecular mechanism of the
responsiveness of the recent clinically identiﬁed PML-RARA
mutations to AS2O3 treatment. Among these mutants, S214L
strikingly disrupted PML-arsenic binding, NB formation,
basal SUMOylation, and degradation. Compared with
S214L, mutation A216T showed moderate defect in AS2O3
response, while mutants L217F and S220G behave similarly
to wild-type PML-RARA (Fig. 2G). These ﬁndings suggest
distinct mutants of PML-RARA confer varying degree of
AS2O3 resistance.
Results from GOTO et al. also reported the missense
mutations of PML-RARA-A216V and L218P occurred in 2
patients with refractory/relapsed APL (Goto et al., 2011).
These two mutations contribute to the aberrant PML-RARA
SUMOylation and NB formation (Goto et al., 2011). When
our work was underway, Liu et al. also demonstrated that
PML-RARA S214L, A216T, L217F and S220G showed
varying resistance to AS2O3 (Liu et al., 2016). In this study,
we detected the direct binding of PML-RARA mutants with
AS2O3. Mutant S214L exhibited no binding to AS2O3,
demonstrating that S214, together with C212/213, is equally
essential for mediating the effect of AS2O3. It is possible that
mutations in these amino acid residues lead to a confor-
mational change in PML structure, which disrupts the
microenvironment for the direct PML-AS2O3 binding and
abolishes the following physiological consequences includ-
ing SUMOylaiton and degradation of PML-RARA. Further
determination of the three dimensional structure of PML-
RARA and PML-RARA-S214L are needed to elucidate the
detailed molecular mechanism.
AS2O3 has been considered as a consolidation treatment
for the relapsed APL patients, which has dramatically
improved the event-free survival and overall survival in APL
patients (Rice and de The, 2014). Mechanism study about
the mutations in PML-RARA for AS2O3 resistance indicates
that higher dosage of AS2O3 or the combination of AS2O3
with chemotherapy might be helpful for those patients har-
boring A216T mutation. The unresponsiveness of S214L to
As2O3 exposure suggests that it is better to choose an
alternative treatment strategy other than As2O3 in relapsed
APL patients.
LETTER Dong-Mei Bai and Xiao-Feng Zheng
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